FI126633B - Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi - Google Patents

Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi Download PDF

Info

Publication number
FI126633B
FI126633B FI20155554A FI20155554A FI126633B FI 126633 B FI126633 B FI 126633B FI 20155554 A FI20155554 A FI 20155554A FI 20155554 A FI20155554 A FI 20155554A FI 126633 B FI126633 B FI 126633B
Authority
FI
Finland
Prior art keywords
domain
loop
src
seq
amino acid
Prior art date
Application number
FI20155554A
Other languages
English (en)
Swedish (sv)
Other versions
FI20155554A (fi
Inventor
Kalle Saksela
Original Assignee
Next Biomed Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Therapies Oy filed Critical Next Biomed Therapies Oy
Priority to FI20155554A priority Critical patent/FI126633B/fi
Priority to US15/742,934 priority patent/US11060084B2/en
Priority to EP21150093.9A priority patent/EP3851536A1/en
Priority to EP16741975.3A priority patent/EP3320095B1/en
Priority to PCT/FI2016/050509 priority patent/WO2017009533A1/en
Priority to CA2991953A priority patent/CA2991953A1/en
Publication of FI20155554A publication Critical patent/FI20155554A/fi
Application granted granted Critical
Publication of FI126633B publication Critical patent/FI126633B/fi
Priority to US17/367,723 priority patent/US20210395726A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (5)

1. Menetelmä rekombinantteja nefrokystiinin (NPHP1] SH3-domeenin, jolla on SEQ ID NO:l:n sekvenssi, johdannaisia käsittävän kirjaston valmistamiseksi, mainitun menetelmän käsittäessä vaiheet: (a] tuotetaan SEQ ID NO:l:n mukaisen NPHP1 SH3-domeenin rekombinantteja johdannaisia vaihtamalla tai lisäämällä vähintään 1 aminohappo mainitun SH3-domeenin RT-luupissa, ja/tai vaihtamalla tai lisäämällä vähintään 1 aminohappo mainitun SH3-domeenin n-src-luupissa, ja (b] rakentamalla kirjasto, joka käsittää vaiheessa (a] tuotettuja SH3-domeenin rekombinantteja johdannaisia; jolloin NPHP1 SH3-domeenin rekombinantit johdannaiset säilyttävät vähintään 85 % identtisyyden SEQ ID NO:l:n aminohapposekvenssiin RT- ja n-src-luuppien ulkopuolella, ja jolloin RT-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 8-17, ja n-src-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 28-34.
2. Patenttivaatimuksen 1 mukainen menetelmä, jolloin vaiheessa (a] kuusi aminohappoa RT-luupissa on satunnaisesti vaihdettu, ja neljä aminohappoa n-src-luupissa on satunnaisesti vaihdettu ja kaksi satunnaista aminohappoa on lisätty n-src-luuppiin.
3. Kirjasto, joka on saatu patenttivaatimuksen 1 tai 2 mukaisella menetelmällä, mainitun kirjaston käsittäessä SEQ ID NO:l:n mukaisen nefrokystiini (NPHP1) SH3-domeenin rekombinantteja johdannaisia, käsittäen vähintään yhden aminohapon vaihdon tai lisäyksen mainitun SH3-domeenin RT-luupissa, ja/tai vähintään yhden aminohapon vaihdon tai lisäyksen mainitun SH3-domeenin n-src-luupissa, jolloin RT-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 8-17, ja n-src-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 28-34, ja vähintään 85 % identtisyyden SEQ ID NO:l:n aminohapposekvenssiin RT- ja n-src-luuppien ulkopuolella.
4. Rekombinanttien sitojaproteiinien valikointimenetelmä patenttivaatimuksen 3 mukaisesta kirjastosta, joka käsittää NPHP1 SH3-domeenin rekombinantteja johdannaisia, mainitun menetelmän käsittäessä vaiheet (a] saatetaan NPHP1 SH3-domeenin johdannaisia käsittävä kirjasto kontaktiin kohdemolekyylin kanssa riittävän ajan olosuhteissa, jotka sallivat johdannaisten ja kohdemolekyylin vuorovaikutuksen, jolloin kohdemolekyyli ei ole NPHP1 SH3-domeenin luonnollinen sitoutumisligandi, ja (b] valikoidaan kirjastosta yksi tai useampi nefrokystiini (NPHP1] SH3-domeenin johdannainen, jolla on spesifistä sitoutumisaktiviteettia kohdemolekyyliin, jolloin valitut NPHP1 SH3-domeenin johdannaiset säilyttävät vähintään 85 % identtisyyden aminohapposekvenssiin SEQ ID NO:l RT- ja n-src-luuppien ulkopuolella, ja jolloin RT-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 8-17, ja n-src-luuppi sijaitsee SEQ ID NO:l:n aminohappopositioissa 28-34.
5. Patenttivaatimuksen 4 mukainen menetelmä, jolloin mainittu kohdemolekyyli on proteiini tai peptidi.
FI20155554A 2015-07-10 2015-07-10 Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi FI126633B (fi)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FI20155554A FI126633B (fi) 2015-07-10 2015-07-10 Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi
US15/742,934 US11060084B2 (en) 2015-07-10 2016-07-08 SH3 domain derivatives
EP21150093.9A EP3851536A1 (en) 2015-07-10 2016-07-08 Sh3 domain derivatives
EP16741975.3A EP3320095B1 (en) 2015-07-10 2016-07-08 Sh3 domain derivatives
PCT/FI2016/050509 WO2017009533A1 (en) 2015-07-10 2016-07-08 Sh3 domain derivatives
CA2991953A CA2991953A1 (en) 2015-07-10 2016-07-08 Sh3 domain derivatives
US17/367,723 US20210395726A1 (en) 2015-07-10 2021-07-06 SH3 domain derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20155554A FI126633B (fi) 2015-07-10 2015-07-10 Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi

Publications (2)

Publication Number Publication Date
FI20155554A FI20155554A (fi) 2017-01-11
FI126633B true FI126633B (fi) 2017-03-15

Family

ID=56511599

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20155554A FI126633B (fi) 2015-07-10 2015-07-10 Menetelmä rekombinantteja nefrokystiinin (NPHP1) SH3-domeenin johdannaisia käsittävän kirjaston valmistamiseksi

Country Status (5)

Country Link
US (2) US11060084B2 (fi)
EP (2) EP3320095B1 (fi)
CA (1) CA2991953A1 (fi)
FI (1) FI126633B (fi)
WO (1) WO2017009533A1 (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20215508A1 (fi) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimeettisiä nanopartikkeleita uusien koronavirusten leviämisen estämiseksi ja infektioasteen alentamiseksi
CN113967257A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种c-Src SH3 RT-loop作为靶点用于抗血栓
WO2023089243A1 (en) * 2021-11-19 2023-05-25 Pandemblock Oy Sh3 domain derivatives targeting receptor binding domain (rbd) of sars-cov-2 spike protein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2201870A1 (en) * 1994-10-07 1996-04-18 Kari Alitalo Cytoplasmic tyrosine kinase bmx protein and dna
US6309820B1 (en) * 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
AU711141B2 (en) * 1995-04-07 1999-10-07 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
EP1181358B1 (en) 1999-05-26 2010-11-17 Next Biomed Technologies NBT Oy Methods and materials for generating sh3 domains with tailored binding properties
GB0025804D0 (en) * 2000-10-20 2000-12-06 Glaxo Group Ltd Assay
WO2007030426A2 (en) * 2005-09-07 2007-03-15 Board Of Regents, The University Of Texas System Methods of using and analyzing biological sequence data
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9593314B2 (en) 2012-03-16 2017-03-14 Covagen Ag Binding molecules with antitumoral activity
MX2015014608A (es) 2013-04-19 2016-03-03 Covagen Ag Novedosas moleculas de union biespecifica con actividad antitumoral.

Also Published As

Publication number Publication date
CA2991953A1 (en) 2017-01-19
US20210395726A1 (en) 2021-12-23
US20180230456A1 (en) 2018-08-16
US11060084B2 (en) 2021-07-13
EP3320095A1 (en) 2018-05-16
EP3851536A1 (en) 2021-07-21
WO2017009533A1 (en) 2017-01-19
EP3320095B1 (en) 2021-01-06
FI20155554A (fi) 2017-01-11

Similar Documents

Publication Publication Date Title
Steiner et al. Efficient selection of DARPins with sub-nanomolar affinities using SRP phage display
US20210395726A1 (en) SH3 domain derivatives
Reverdatto et al. Peptide aptamers: development and applications
Hackel et al. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling
Frei et al. Protein and antibody engineering by phage display
Pande et al. Phage display: concept, innovations, applications and future
WO2002103363A2 (en) Selection by avidity capture
US8969253B2 (en) Method for screening phage display libraries against each other
AU2014229549B2 (en) Scaffolded peptidic libraries and methods of making and screening the same
Nelson et al. Synthetic antibody libraries
CA2905529A1 (en) An integrated system for library construction, affinity binder screening and expression thereof
Chevrel et al. Alpha repeat proteins (αRep) as expression and crystallization helpers
Li et al. Revisiting the phosphotyrosine binding pocket of Fyn SH2 domain led to the identification of novel SH2 superbinders.
Dreier et al. Rapid selection of high-affinity antibody scFv fragments using ribosome display
US20150315566A1 (en) Method for generating high affinity, bivalent binding agents
Jacobs et al. FN3 domain engineering
Petrenko et al. Vectors and modes of display
Kalichuk et al. Affitins: ribosome display for selection of Aho7c-based affinity proteins
US11001833B2 (en) Method and kit for generating high affinity binding agents
US11473080B2 (en) Method for generating high affinity, bivalent binding agents for sandwich assays
Kramer et al. Challenges of γ9δ2TCR affinity maturation when using phage display
Gazarian Drug discovery and design via high throughput screening of combinatorial phage-display protein-peptide libraries
Willemsen et al. Protein engineering
Kierny Generating Recombinant Affinity Reagents by Phage-and Ribosome-Display
Giordano et al. Check for updates

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 126633

Country of ref document: FI

Kind code of ref document: B